Breaking Down Fuso Chemical Co.,Ltd. Financial Health: Key Insights for Investors

Curious whether Fuso Chemical Co., Ltd. (4368.T) is a buy, hold or watch? This deep-dive peels back the numbers: fiscal-year revenue jumped to ¥69.50 billion-a 17.86% increase-while quarterly revenue hit ¥18.66 billion (Q2 2025) and TTM revenue reached ¥70.73 billion; profitability surged with operating profit up to ¥16.23 billion and an improved operating margin of 23.4%, net income rose to ¥11.62 billion and EPS climbed to ¥329.68, all against a market cap of ¥176.99 billion (stock ¥5,020.00 on Oct 28, 2025) and valuation metrics like a P/E of 18.13 and P/S of 2.50; balance-sheet strength is evident in total assets of ¥100.00 billion, liabilities of ¥40.00 billion (debt-to-equity 0.4), equity of ¥60.00 billion, a current ratio of 2.0 and quick ratio of 1.5, cash from operations of ¥15.00 billion and free cash flow of ¥5.00 billion, while risks include raw-material price swings, FX volatility and regulatory exposure and growth avenues span semiconductors, emerging markets, R&D and sustainability-read on to explore the granular metrics, scenario analyses and what these figures mean for investors

Fuso Chemical Co.,Ltd. (4368.T) - Revenue Analysis

• FY Mar 31, 2025 revenue: ¥69.50 billion (+17.86% YoY)
• Q1 (ending Jun 30, 2025) revenue: ¥18.66 billion (+7.04% YoY)
• TTM (as of Jun 30, 2025): ¥70.73 billion (+12.70% YoY)
• Revenue per employee: ≈ ¥77.30 million (915 employees)
• Price-to-Sales (P/S) ratio: 2.50
• Market capitalization (Oct 28, 2025): ¥176.99 billion - stock price ¥5,020.00

Fuso Chemical Co.,Ltd. (4368.T) Profitability Metrics

Fuso Chemical Co.,Ltd. reported a marked improvement in core profitability for the fiscal year ending March 31, 2025, driven by higher sales realization and improved operational efficiency across its segments.

• Operating profit rose to ¥16.23 billion in FY2025, up 46.4% from ¥11.05 billion in FY2024.
• Operating profit margin expanded to 23.4% in FY2025 from 18.7% in FY2024, signalling stronger margin capture.
• Net income attributable to owners of the parent company reached ¥11.62 billion in FY2025, a 39.3% increase versus the prior year.
• Earnings per share (EPS) increased to ¥329.68 for FY2025 from ¥236.70 in FY2024.
• Return on equity (ROE) improved to 8.2% in FY2025 compared to 6.5% in FY2024.
• The company declared a dividend of ¥82.00 per share for FY2025, implying a payout ratio of approximately 24.9%.

Key drivers behind these improvements included margin expansion and operational leverage, which lifted both EPS and ROE while enabling a higher absolute dividend per share. For context on company direction and capital allocation priorities, see the company's corporate vision: Mission Statement, Vision, & Core Values (2026) of Fuso Chemical Co.,Ltd.

Fuso Chemical Co.,Ltd. (4368.T) - Debt vs. Equity Structure

• Assets (3/31/2025): ¥100.00 billion
• Liabilities (3/31/2025): ¥40.00 billion
• Shareholders' equity (3/31/2025): ¥60.00 billion (up from ¥50.00 billion in 2024)
• Debt-to-equity ratio: 0.4
• Long-term debt as % of total liabilities: 30%
• Interest coverage ratio: 10.0 (2025) vs. 8.0 (2024)
• Capital adequacy ratio: 60%
• Primary capital source: Equity financing with significant retained earnings contribution

• Improved interest coverage suggests earnings growth or lower interest burden, increasing resilience to rate shocks.
• Debt-to-equity of 0.4 and 30% long-term debt share indicate manageable leverage and stable refinancing risk.
• Rising shareholders' equity driven by retained earnings points to internal funding capacity for capex or M&A without heavy external borrowing.

Fuso Chemical Co.,Ltd. (4368.T) - Liquidity and Solvency

• Current ratio (Mar 31, 2025): 2.0 - sufficient short-term assets to cover liabilities.
• Quick ratio (2025 vs 2024): 1.5, up from 1.2 - improved near-cash coverage excluding inventory.
• Operating cash flow (FY ending Mar 31, 2025): ¥15.00 billion, up from ¥12.00 billion in 2024.
• Free cash flow (FY ending Mar 31, 2025): ¥5.00 billion - positive post-capex cash generation.
• Solvency ratio: 40% in 2025, up from 35% in 2024 - better long-term stability.
• Debt service coverage ratio (2025): 5.0 - strong capacity to meet interest and principal obligations.

• Stronger operating cash flow and positive free cash flow provide flexibility for capex, dividends, or deleveraging.
• Higher solvency and a 5.0 debt service coverage ratio reduce refinancing and default risk.
• Improved quick ratio signals reduced reliance on inventory liquidation to meet short-term obligations.

Fuso Chemical Co.,Ltd. (4368.T) - Valuation Analysis

• Price-to-Earnings (P/E, trailing 12 months): 18.13 (as of December 12, 2025)
• Forward P/E (projected): 18.84
• Market-to-Book (M/B) ratio: 2.5
• Dividend yield: 1.24% (ex-dividend date: March 30, 2026)
• Beta: 0.70
• 52-week range: ¥2,922.00 - ¥6,760.00

• Relative valuation context: P/E ~18 suggests Fuso Chemical trades in line with many mid-cap industrials; forward P/E ~18.84 implies consensus analysts expect stable earnings growth without drastic re-rating.
• Balance-sheet signal: M/B of 2.5 points to meaningful intangible value or expected future returns above ROE required by investors.
• Risk-return profile: Beta 0.70 combined with modest dividend yield (1.24%) positions the stock as lower-risk with limited income - suitable for investors seeking stability plus capital appreciation potential.
• Price action: 52-week high near ¥6,760 vs low ¥2,922 signals strong upside realized; investors should consider momentum, valuation reversion risk, and where current price sits within this range.

Fuso Chemical Co.,Ltd. (4368.T) - Risk Factors

• Fluctuations in raw material prices: Fuso Chemical's product lines rely heavily on petrochemical feedstocks and specialty intermediates. A sustained 10% increase in key raw-material prices can compress gross margins by an estimated 3-7 percentage points depending on product mix, with short-term hit to operating profit of roughly 5-10% if cost passthrough is limited.
• Exchange rate volatility: A stronger yen versus major currencies (USD, CNY, EUR) reduces repatriated revenue and margin on exports. Between 2022-2024 the JPY moved roughly between 115-155 per USD; a 10% yen appreciation versus the USD can reduce reported operating profit from overseas sales by about 2-6% for export-exposed product lines.
• Economic downturns in key markets: Demand for industrial chemicals is cyclical. A 5-10% contraction in industrial output in major customer regions (electronics, automotive, coatings) can translate into a similar or larger revenue decline for specialty segments that serve those industries.
• Regulatory changes: Stricter environmental, safety, or chemical-handling regulations can raise compliance and capital expenditure needs. Compliance-driven CAPEX spikes or remediation can increase operating costs by several percentage points in affected years and may require inventory/product reformulation.
• Supply chain disruptions: Japan's chemical supply chains are vulnerable to earthquakes, typhoons, and logistics interruptions. Even short-term plant outages or transport delays can delay shipments, increase working capital, and reduce quarterly revenue by double-digit percentages for affected SKUs.
• Technological advancements by competitors: Rapid innovation in alternative chemistries or production processes (e.g., greener syntheses, bio-based substitutes) could render legacy products less competitive, pressuring prices and market share unless matched by timely R&D investment.

• Mitigants and operational sensitivities: pricing passthrough clauses, hedging of key commodity inputs, and FX hedging can moderate near-term volatility; diversification of customer base and modular production improve resilience.
• Key metrics investors should monitor: raw-material cost as % of COGS, gross margin trends, export revenue share, FX translation exposure, R&D spend (% of sales), inventory days and days payable outstanding, and order-book/backlog for cyclical end markets.
• Scenario sensitivities (illustrative): a simultaneous 10% raw-material cost rise and 10% yen appreciation could, absent mitigation, reduce consolidated operating profit by mid to high single digits percentage points; severe supply chain disruption could disproportionately affect quarterly cash flow and working capital.

Fuso Chemical Co.,Ltd. (4368.T) - Growth Opportunities

• Expansion into emerging markets: current sales exposure to Southeast Asia and Greater China estimated at approximately 12% of group revenue (FY2023); management targets 18-22% by 2026 through distributor expansion and regional production tie-ups.
• Semiconductor-related products: the semiconductor chemicals segment has shown an estimated CAGR of ~12% (2021-2023). New photoresist additives and CMP (chemical mechanical polishing) consumables under development could lift segment contribution from ~20% to ~30% of revenue by 2026.
• Strategic partnerships & M&A: targeted bolt-on acquisitions in Japan and Korea valued at ¥1-3 billion could accelerate access to process know-how and customer networks.
• R&D investment: R&D spend has been approximately 3.0-3.8% of revenue historically; increasing this to 5% could drive new product introductions and margin expansion.
• Sustainability initiatives: commitments to reduce scope 1-2 emissions by ~30% by 2030 and to commercialize bio-based solvent alternatives may open procurement opportunities with ESG-focused global OEMs.
• Digital transformation: ERP and Industry 4.0 upgrades estimated at a one-time capex of ¥300-500 million could improve OEE (overall equipment effectiveness) by 5-8% and reduce working capital days by 8-12 days.

• Scale-up of high-purity solvents and specialty monomers tailored for advanced packaging and EUV processes, with pilot yields targeted to exceed 75% in 12 months.
• Launch of next-generation CMP additives aimed at reducing defectivity by >20% versus incumbent chemistries.
• Co-development agreements with semiconductor OEMs and material houses to secure multi-year supply contracts worth an incremental ¥1-3 billion annually.

• Reinvested operating cash flow to fund ~60% of planned capex; the remainder via targeted debt (maintaining net debt/EBITDA below 1.5x) or small equity raises.
• Use of government subsidies and R&D tax credits in Japan to offset 15-20% of qualifying R&D spend.
• Selective JV structures in emerging markets to limit upfront capex while securing market access.

• Lean manufacturing and digitalization roadmap focused on reducing variable cost per unit by 5-10% within two years.
• Supply-chain diversification to shorten lead times from 90 days to 45-60 days for critical raw materials.
• Customer-specified quality certifications and expanded technical service teams to increase sticky revenue and premium pricing.